Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (255)	6/26/2002 7:10:52 PM
From: Czechsinthemail	Respond to of 598

Nice finds! I looked at the abstract. Could you provide some background regarding what kinds of conditions or disorders are modulated by the STAT4 and STAT6 transcription factors? The abstract also suggested these compounds were useful in diagnosing conditions dependent on STAT signaling. I assume this might lead to a partnership around a diagnostic test.

To: scaram(o)uche who wrote (255)	6/26/2002 7:23:55 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 598

Baird: The diagnostic part is just attorney BS, trying for all the breadth known to mankind. STAT4 regulation (down) would lead to a decrease in the production of IFNgamma and therefore modulation of disease mediated by TH1 cells....... multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, etc. STAT6 inhibition might be of interest for asthma, parasitic infections and other stuff that I don't have a clue about given that I'm spouting jargon. STAT6 activation is required for TH2 responses. This is all "moving target" theory, of course. Rick